Here are the two trials you need to know about from the Society of Interventional Radiology (SIR) 2013 meeting. The buzz these days is around stent grafts for dialysis access, and embolization as a treatment for benign prostatic hyperplasia (BPH).
Early results from RENOVA: Stent grafts successful for dialysis access
The SIR abstract of the year
came from SIR past-president Dr. Ziv Haskal, who outlined early results from the RENOVA trial. These results demonstrated that stent grafts were much more durable and lasted longer than previously expected, with the stent graft group consistently outperforming the angioplasty group across a variety of metrics. He was encouraging us to start thinking of stent grafts as long-term tools; they reduce the amount of follow up and re-intervention for dialysis patients, and thus improve their quality of life.
W. L. Gore's Flair stent graft was used in the trial. This will be a huge boon to Gore, who already has FDA approval for the graft for the treatment of venous anastomotic stenosis in hemodialysis access grafts. The market potential for this indication is significant, with nearly 400,000 people undergoing dialysis each year. Adoption of stent grafts in this indication, however, would cannibalize percutaneous transluminal angioplasty (PTA) balloon catheter use in the arteriovenous access indication, which accounts for over 30% of PTA balloon catheter sales.
The trial was praised for being a randomized, prospective trial, which is expected to have a cost-effectiveness component when full data become available. It was pointed out that this kind of data will be key to supporting reimbursement for stent grafts in a dialysis indication.